Novo Nordisk to Offer Wegovy Pill in US for $149/Month

• Lower-dose pills (1.5mg and 4mg) priced at $149/month initially, with 4mg rising to $199/month from April 15, 2026
• Higher-dose pills (9mg and 25mg) available at $299/month for self-paying patients
• The oral pill contains the same active ingredient (semaglutide) as injectable Wegovy and Ozempic, helping Novo regain market share from competitor Eli Lilly

Summary: Novo Nordisk to Offer Wegovy Pill in US for $149/Month

Danish pharmaceutical company Novo Nordisk announced on January 5 it will launch oral Wegovy weight loss pills for self-paying U.S. patients at tiered pricing. The lower-dose pills (1.5mg and 4mg) will cost $149 per month, while higher-dose versions (9mg and 25mg) are priced at $299 monthly.

Key Pricing Details:

• 1.5mg and 4mg doses: $149/month starting January 5
• 9mg and 25mg doses: $299/month starting January 5
• 4mg dose will increase to $199/month from April 15

Product Information:

The oral pills contain semaglutide, the same active ingredient found in injectable Wegovy and Ozempic. Novo Nordisk already markets an oral semaglutide product called Rybelsus for type 2 diabetes treatment. The U.S. Food and Drug Administration approved the pill on December 22.

Market Implications:

This launch represents a strategic move by Novo Nordisk to regain market share from competitor Eli Lilly in the lucrative weight loss medication sector. The pill format offers a more convenient alternative to injectable versions, potentially expanding the addressable market. The competitive pricing for self-pay patients could drive adoption among those without insurance coverage for weight loss medications, a significant barrier in the current market.

The tiered pricing strategy allows Novo Nordisk to serve different patient segments while the scheduled price increase for the 4mg dose in April suggests an introductory promotional period to establish market presence.